In early December 2019, the first cases of a new coronavirus emerged, a virus that has since come to grip the world’s media and worry regulators in every country.
With echoes of the 2002 SARS epidemic, the pathogen - shortly dubbed COVID-19 by the World Health Organization (WHO) - originated in China and was thought to have derived from a mutation occurring at a since-closed animal market in the city of Wuhan.
With a population of 11 million, Wuhan is a major commercial and industrial hub with large streams of people arriving and departing, prior to the Chinese government’s effective shutdown of the area.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze